collection
MENU ▼
Read by QxMD icon Read
search

Urticaria

shared collection
20 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28078079/looking-forward-to-new-targeted-treatments-for-chronic-spontaneous-urticaria
#1
REVIEW
Emek Kocatürk, Marcus Maurer, Martin Metz, Clive Grattan
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/27995273/-partial-response-of-solar-urticaria-to-omalizumab-therapy
#2
L Kowalzick, W Thiel, C Bielfeld, H Ziegler, L Eickenscheidt
The treatment of solar urticaria is regarded as difficult. In some cases good responses to the anti-IgE antibody omalizumab (Xolair®), approved for treatment of chronic spontaneous urticaria, have been reported. We report on a 50-year-old Caucasian woman who for the last 5 years has developed localized itching and stinging erythemas following exposure to sunlight accompanied sometimes by anaphylactic reactions. Oral antihistamines in three- to four-fold doses and a topical sun screen had been only partially effective in long-term use...
December 19, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27996138/antihistamine-updosing-in-chronic-urticaria-is-there-enough-evidence
#3
K Weller, M Maurer
No abstract text is available yet for this article.
December 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27979029/chronic-autoimmune-urticaria-as-the-presenting-manifestation-of-primary-hyperparathyroidism
#4
Amie Harvey, Karen Kaufman, Jason Daily
No abstract text is available yet for this article.
December 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27970590/adaptive-prediction-of-symptoms-return-upon-discontinuation-of-omalizumab-treatment-in-chronic-spontaneous-urticaria-patients
#5
D Saldana Miranda, M Ferrer, N Janssens, A Gimenez-Arnau, M Balp, S Khalil, V Risson
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27942227/aquagenic-urticaria-diagnostic-and-management-challenges
#6
REVIEW
Robert Rothbaum, Jean S McGee
Aquagenic urticaria (AU) is a rare inducible form of physical urticaria, which occurs in response to cutaneous exposure to water, including sweat and tears. Patients present with characteristic 1-3 mm folliculocentric wheals with surrounding 1-3 cm erythematous flares within 20-30 minutes following skin contact with water. In rare cases, there are concomitant systemic symptoms, such as wheezing or shortness of breath. The pathogenesis of AU is poorly understood at this time, and it appears to be mediated in both a histamine-dependent and independent manner...
2016: Journal of Asthma and Allergy
https://www.readbyqxmd.com/read/27932886/comparative-efficacy-of-bilastine-levocetirizine-and-desloratadine-updosing-in-chronic-urticaria
#7
COMMENT
Maria T Staevska
No abstract text is available yet for this article.
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27690471/clinical-practice-guideline-for-diagnosis-and-management-of-urticaria
#8
Kanokvalai Kulthanan, Papapit Tuchinda, Leena Chularojanamontri, Pattriya Chanyachailert, Wiwat Korkij, Amornsri Chunharas, Siriwan Wananukul, Wanida Limpongsanurak, Suwat Benjaponpitak, Wanee Wisuthsarewong, Kobkul Aunhachoke, Vesarat Wessagowit, Pantipa Chatchatee, Penpun Wattanakrai, Orathai Jirapongsananuruk, Jettanong Klaewsongkram, Nopadon Noppakun, Pakit Vichyanond, Puan Suthipinittharm, Kiat Ruxrungtham, Srisupalak Singalavanija, Jarungchit Ngamphaiboon
Urticaria is a common skin condition that can compromise quality of life and may affect individual performance at work or school. Remission is common in majority of patients with acute spontaneous urticaria (ASU); however, in chronic cases, less than 50% had remission. Angioedema either alone or with urticaria is associated with a much lower remission rate. Proper investigation and treatment is thus required. This guideline, a joint development of the Dermatological Society of Thailand, the Allergy, Asthma, and Immunology Association of Thailand and the Pediatric Dermatological Society of Thailand, is graded and recommended based on published evidence and expert opinion...
September 2016: Asian Pacific Journal of Allergy and Immunology
https://www.readbyqxmd.com/read/27926978/potential-blood-biomarkers-in-chronic-spontaneous-urticaria
#9
REVIEW
P Kolkhir, F André, M K Church, M Maurer, M Metz
Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that is defined as the recurrence of weals, angioedema or both for > 6 weeks due to known or unknown causes. As of yet, disease diagnosis is purely clinical. Objective tools are needed to monitor the activity of CSU and the efficacy of treatment. Recently, several reports have suggested that blood parameters may be considered as potential disease-related biomarkers. Here, we reviewed available literature on blood biomarkers for CSU diagnosis, activity monitoring, duration, patient subgroup allocation or response to treatment...
January 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/24522090/development-and-validation-of-the-urticaria-control-test-a-patient-reported-outcome-instrument-for-assessing-urticaria-control
#10
Karsten Weller, Adriane Groffik, Martin K Church, Tomasz Hawro, Karoline Krause, Martin Metz, Peter Martus, Thomas B Casale, Petra Staubach, Marcus Maurer
BACKGROUND: Chronic urticaria is a frequent and debilitating skin disease. Its symptoms commonly fluctuate considerably from day to day. As of yet, the only reliable tool to assess disease activity is the Urticaria Activity Score, which prospectively documents the signs and symptoms of urticaria for several days. OBJECTIVE: We sought to develop and validate a novel patient-reported outcome instrument to retrospectively assess urticaria control, the Urticaria Control Test (UCT)...
May 2014: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27886909/clinical-measures-of-chronic-urticaria
#11
REVIEW
Karsten Weller, Frank Siebenhaar, Tomasz Hawro, Sabine Altrichter, Nicole Schoepke, Marcus Maurer
The use of standardized, valid, and reliable clinical measures is an important element in modern patient management, particularly in diseases that are not objectively assessable and are associated with a high disease burden. Chronic urticaria is such a disorder for which several new and well-developed clinical measures became available. These measures comprise tools to assess disease activity, disease control, and health-related quality-of-life impairment. This review provides an overview of the currently available clinical measures for chronic urticaria...
February 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/27886913/biologics-in-chronic-urticaria
#12
REVIEW
Adeeb Bulkhi, Andrew J Cooke, Thomas B Casale
Chronic urticaria (CU) is defined as wheals, angioedema, or both, that last more than 6 weeks. Second-generation antihistamines are considered the first-line therapy for CU. Unfortunately, many patients will fail antihistamines and require alternative therapy, including immune response modifiers or biologics. Multiple biological agents have been evaluated for use in antihistamine-refractory CU, including omalizumab, rituximab, and intravenous immunoglobulin; omalizumab is the most efficacious. Because of the success of omalizumab, multiple new biologics that are directed at the IgE pathway are under investigation...
February 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/27759482/dermatologic-uses-of-omalizumab
#13
Justin C Chia, P Régine Mydlarski
PURPOSE: Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of immunoglobulin E (IgE) to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Omalizumab has been approved for use in asthma, and new reports show promise in a variety of dermatologic diseases. Herein, we review the literature on omalizumab in dermatology and discuss the safety, efficacy and mechanisms of action for this emerging therapy. MATERIALS AND METHODS: PubMED, MEDLINE and Embase databases were searched for the period 1 January 1990 to 1 September 2016...
November 7, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27861988/mechanisms-of-action-that-contribute-to-efficacy-of-omalizumab-in-chronic-spontaneous-urticaria
#14
REVIEW
Allen P Kaplan, Ana M Giménez-Arnau, Sarbjit Singh Saini
The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically "abnormal" IgE, and decreasing in vitro coagulation abnormalities associated with disease activity...
November 15, 2016: Allergy
https://www.readbyqxmd.com/read/27826098/a-randomized-multicenter-study-evaluating-xolair%C3%A2-persistency-of-response-after-long-term-therapy-xport
#15
Dennis Ledford, William Busse, Benjamin Trzaskoma, Theodore A Omachi, Karin Rosén, Bradley E Chipps, Allan T Luskin, Paul G Solari
BACKGROUND: Few data are available to assist clinicians with decisions regarding long-term use of asthma therapies, including omalizumab. OBJECTIVE: To evaluate the benefit and persistency of response in subjects continuing or withdrawing from long-term omalizumab treatment. METHODS: Evaluating the Xolair® Persistency Of Response After Long-Term Therapy (XPORT) was a randomized, double-blind, placebo-controlled withdrawal study that included subjects with moderate-to-severe persistent asthma receiving long-term omalizumab...
November 5, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27788887/tolerance-to-nonsteroidal-anti-inflammatory-drugs-and-alcohol-after-omalizumab-treatment-in-a-patient-with-chronic-urticaria
#16
Kristen M Walters, Andrew A White
No abstract text is available yet for this article.
November 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27777182/autoimmune-chronic-spontaneous-urticaria-what-we-know-and-what-we-do-not-know
#17
Pavel Kolkhir, Martin K Church, Karsten Weller, Martin Metz, Oliver Schmetzer, Marcus Maurer
Chronic spontaneous urticaria (CSU) is a mast cell-driven skin disease characterized by the recurrence of transient wheals, angioedema, or both for more than 6 weeks. Autoimmunity is thought to be one of the most frequent causes of CSU. Type I and II autoimmunity (ie, IgE to autoallergens and IgG autoantibodies to IgE or its receptor, respectively) have been implicated in the etiology and pathogenesis of CSU. We analyzed the relevant literature and assessed the existing evidence in support of a role for type I and II autoimmunity in CSU with the help of Hill's criteria of causality...
October 21, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27720581/omalizumab-for-the-treatment-of-chronic-spontaneous-urticaria-in-clinical-practice
#18
Maria Rita Bongiorno, Nunzio Crimi, Salvatore Corrao, Alberto Allotta, Antonino Arena, Ignazio Brusca, Enrico Heffler, Giovanna Malara, Mirella Milioto, Giuseppe Pistone, Morena Porto, Emilio Raia, Giuseppe Valenti
No abstract text is available yet for this article.
December 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27593503/cosmetic-components-causing-contact-urticaria-a-review-and-update
#19
REVIEW
Lien Verhulst, An Goossens
Immediate skin reactions are common in dermatological practice, but may often be overlooked. The main objective of this article is to provide an update of the literature concerning immediate-type reactions or contact urticaria/contact urticaria syndrome caused by cosmetic ingredients in terms of immediate clinical symptoms, positive reactions following open, scratch or, most often, prick testing, and sometimes the detection of specific IgE antibodies. To this end, a selective search in different medical literature databases was performed...
December 2016: Contact Dermatitis
https://www.readbyqxmd.com/read/27286499/controversies-and-challenges-in-the-management-of-chronic-urticaria
#20
REVIEW
P Staubach, T Zuberbier, C Vestergaard, F Siebenhaar, E Toubi, G Sussman
This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Despite the clear international guideline, there remain a number of controversies and challenges in the management of patients with chronic urticaria (CU). As a result of major advancements in urticaria over the past 4 years, the current EAACI/GA(2) LEN/EDF/WAO urticaria guideline treatment algorithm requires updating. Case studies from patients with chronic spontaneous urticaria (CSU) [also called chronic idiopathic urticaria (CIU)], chronic inducible urticaria (CIndU) or diseases and syndromes related to CU are useful in describing and exploring challenges in disease management...
July 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
label_collection
label_collection
7989
1
2
2016-10-06 00:09:21
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"